Status:
UNKNOWN
Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning
Lead Sponsor:
Ping Liang
Conditions:
Hepatocellular Carcinoma
Contrast-enhanced Ultrasound
Eligibility:
All Genders
18+ years
Brief Summary
Developing a deep learning model based on contrast-enhanced ultrasound (CEUS) to predict the prognosis of hepatocellular carcinoma (HCC) and aid choose operation decisions
Detailed Description
Collecting CEUS and clinical data of HCC from different institutions retrospectively. Developing a deep learning model based on CEUS to predict the prognosis of HCC. Developing a deep learning model ...
Eligibility Criteria
Inclusion
- patients with HCC (Ia, Ib, IIa stage) China liver cancer staging who underwent resection or ablation
- without macro-vascular invasion
- Child-Pugh A/B grade
- HCC is proved by pathological examination or two enhanced imaging
- CEUS (Sonovue or Sonozoid) images are performed two weeks before the operation
- Invasive biomarker or prognosis of HCC available
- CEUS images are included in at least three stages (Arterial phase, Portal phase, and Late phase)
Exclusion
- postop follow-up loss or expired less than 3 months
- patients with co-malignancy
- poor images quality for analyzing
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05257694
Start Date
January 1 2022
End Date
December 31 2025
Last Update
October 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853